NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Friday, July 4, 2025 12:00 AM

Conditions: Large B-cell Lymphoma Interventions: Drug: NT-17; Biological: CAR T-cell therapy Sponsors: Washington University School of Medicine; NeoImmuneTech Not yet recruiting

Advancing Biopsychosocial Care Training Initiative

Friday, July 11, 2025 12:00 AM

Conditions: Weight Management; Obesity Prevention; Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Obesity Interventions: Other: Comprehensive Multidisciplinary Obesity Care; Other: Implementation as Usual Control Sponsors: ...

Adapting, Implementing and Evaluating the Effectiveness of HARP for People With Disabilities

Tuesday, July 1, 2025 12:00 AM

Conditions: Disabilities Physical; Falls; Fall Prevention; Adults Interventions: Behavioral: Adapted HARP Sponsors: Washington University School of Medicine Not yet recruiting

Improving Maternal Cardiovascular Outcomes Through the Implementation of a Hypertensive Disorders of Pregnancy Bundle in Nigeria

Wednesday, July 2, 2025 12:00 AM

Conditions: Hypertensive Disorder of Pregnancy Interventions: Other: Hypertension Disorders of Pregnancy (HDP) Implementation Bundle Sponsors: Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI) Recruiting

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Thursday, July 3, 2025 12:00 AM

Conditions: Glioblastoma Interventions: Drug: Azeliragon; Drug: Temozolomide; Radiation: Radiation therapy; Procedure: Surgery or LITT Sponsors: Washington University School of Medicine; Cantex Pharmaceuticals Not yet recruiting

Role of KATP Channel Loss in Type 2 Diabetes

Friday, July 4, 2025 12:00 AM

Conditions: Obesity and Type 2 Diabetes Interventions: Drug: 10 mg glipizide ingestion Sponsors: Washington University School of Medicine; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Wednesday, July 2, 2025 12:00 AM

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Cancer of the Pancreas Interventions: Drug: Zunsemetinib; Drug: mFOLFIRINOX Sponsors: Washington University School of Medicine; National Cancer Institute (NCI); ...

Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

Thursday, July 3, 2025 12:00 AM

Conditions: LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) Sponsors: Nationwide Children's Hospital; National Institute of Neurological Disorders and Stroke (NINDS); Ann & Robert H Lurie Children's Hospital of Chicago; ...